Leukemia

Why trials studying Leukemia stopped, in this sample of ClinicalTrials.gov.

39 stopped trials with a clear reason; 82% ended for non-scientific reasons.

Trials

• Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
  NCT07071909 · WITHDRAWN · funding business
  “Funding unavailable”
• ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
  NCT05655546 · TERMINATED · regulatory
  “On May 13, 2024, the FDA released a communication that Cue Health tests should no longer be used.”
• Natural Killer Cell (CYNK-001) Infusions in Adults with AML
  NCT04310592 · TERMINATED · funding business
  “Business reasons”
• Physical Activity Adapted at Home Supervised by Videoconferencing in Post-cancer for Children / AYA Treated for Leukemia (ONCOPED SAPATIC)
  NCT04136665 · TERMINATED · slow accrual
  “Not enough patient”
• Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
  NCT03759184 · TERMINATED · slow accrual
  “The study was closed after \> 1 year of inactivity.”
• HeartPhone Cancer Survivors Trial 2019
  NCT03953326 · TERMINATED · futility
  “Futility in recruitment”
• Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)
  NCT03016130 · TERMINATED · safety
  “Interim analysis determined that study reached a safety stopping rule”
• The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown Theatrical Performance on Quality of Life and the Therapeutic Process of Patients Undergoing Allogenic Stem Cell Transplantation
  NCT02976558 · TERMINATED · logistics pi
  “Due to organisational issues, the study had to be completed prematurely.”
• Medical Treatment Decision Making Using Adaptive Conjoint Analysis
  NCT02608307 · TERMINATED · slow accrual
  “Slow accrual and COVID-19 restrictions”
• An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
  NCT02225574 · TERMINATED · slow accrual
  “Slow Accrual - Only 1 patient enrolled in Phase 1 - Study never went to Phase II”
• Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60
  NCT02234037 · TERMINATED · slow accrual
  “Slow accrual”
• Ultrasound Use for Difficult Lumbar Punctures in Pediatric Oncology Patients
  NCT01643291 · TERMINATED · slow accrual
  “We were unable to recruit subjects for this study.”
• Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot
  NCT01615146 · TERMINATED · slow accrual
  “Poor recruitment”
• Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant
  NCT01077440 · TERMINATED · logistics pi
  “PI leaving institution”
• Outpatient Neutropenic Diet Study
  NCT00947648 · TERMINATED · slow accrual
  “Slow Accrual”
• A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
  NCT00829647 · WITHDRAWN · slow accrual
  “Unable to enroll”
• Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)
  NCT00800566 · WITHDRAWN · funding business
  “Sponsor terminated.”
• Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
  NCT00555048 · TERMINATED · slow accrual
  “Low accrual”
• Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines
  NCT00514189 · TERMINATED · slow accrual
  “Terminated early due to slow accrual.”
• Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
  NCT00480987 · TERMINATED · funding business
  “Lack of support.”
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
  NCT00362466 · TERMINATED · slow accrual
  “Insufficient Enrollment”
• Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
  NCT00234000 · TERMINATED · slow accrual
  “The study was closed due to poor enrollment”
• Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies
  NCT00356928 · TERMINATED · slow accrual
  “Poor accrual”
• Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
  NCT00827099 · TERMINATED · safety
  “Unacceptable morbidity \& mortality”
• Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia
  NCT00245115 · TERMINATED · manufacturing supply
  “Expiration of study supply”
• Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
  NCT00608517 · TERMINATED · slow accrual
  “slow accrual”
• G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
  NCT00253552 · TERMINATED · logistics pi
  “Terminated at request of PI as study was outdated.”
• Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)
  NCT00500240 · TERMINATED · futility
  “Terminated early due to futility.”
• Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
  NCT00074490 · TERMINATED · slow accrual
  “Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2”
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
  NCT00255684 · TERMINATED · slow accrual
  “low accrual”
• CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
  NCT00369291 · TERMINATED · slow accrual
  “Slow accrual”
• Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
  NCT00062231 · TERMINATED · slow accrual
  “low accrual”
• Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
  NCT00301912 · WITHDRAWN · slow accrual
  “Withdrawn because study never opened to accrual”
• Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
  NCT00069992 · TERMINATED · slow accrual
  “Closed due to competing protocols”
• Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
  NCT00023881 · TERMINATED · futility
  “Lack of efficacy”
• Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
  NCT00014560 · TERMINATED · safety
  “Medarex (supplier of BsAb) stopped study due to toxicities experienced at other sites on unrelated trials halting manufacturing of BsAb”
• Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
  NCT00004933 · TERMINATED · slow accrual
  “Poor accrual”
• 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
  NCT00004058 · TERMINATED · other
  “At this time it is felt that we will not gain further information from an additional patients.”
• Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia
  NCT00002961 · TERMINATED · slow accrual
  “poor accrual”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.